These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3464268)

  • 21. Long-term tacrine treatment in Alzheimer's disease.
    Farré M; Roset PN
    Lancet; 1996 Oct; 348(9035):1181-2. PubMed ID: 8888211
    [No Abstract]   [Full Text] [Related]  

  • 22. Approaches to rational drug development in Alzheimer's disease.
    Iversen LL; Iversen SD; Freedman SB; Dawson G; Rupniak N; Hargreaves RJ; Showell GA; Street LJ; Baker R
    Drug Des Discov; 1993; 9(3-4):251-9. PubMed ID: 8400006
    [No Abstract]   [Full Text] [Related]  

  • 23. AF102B: rational treatment strategy for Alzheimer's disease: recent advances.
    Fisher A; Brandeis R; Karton I; Pittel Z; Dachir S; Sapir M; Grunfeld Y; Levy A; Heldman E
    Adv Neurol; 1990; 51():257-9. PubMed ID: 2403717
    [No Abstract]   [Full Text] [Related]  

  • 24. New drug interventions in Alzheimer's disease.
    Stern GM
    Curr Opin Neurol Neurosurg; 1992 Feb; 5(1):100-3. PubMed ID: 1623227
    [No Abstract]   [Full Text] [Related]  

  • 25. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for the pharmacological treatment of Alzheimer's disease.
    Brinkman SD; Largen JW
    Tex Med; 1987 Jan; 83(1):26-30. PubMed ID: 3824229
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease.
    Hamuro A
    Aust N Z J Psychiatry; 2013 Jun; 47(6):583. PubMed ID: 23093052
    [No Abstract]   [Full Text] [Related]  

  • 28. Physostigmine reversal of scopolamine-induced hypofrontality.
    Prohovnik I; Arnold SE; Smith G; Lucas LR
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):220-8. PubMed ID: 9040502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frontoparietal cognitive control of verbal memory recall in Alzheimer's disease.
    Dhanjal NS; Wise RJ
    Ann Neurol; 2014 Aug; 76(2):241-51. PubMed ID: 24933580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical drug trials in Alzheimer's disease.
    Crook T
    Ann N Y Acad Sci; 1985; 444():428-36. PubMed ID: 3893271
    [No Abstract]   [Full Text] [Related]  

  • 31. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacological correction of Alzheimer's disease (review of the literature)].
    Groppa SA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(9):110-6. PubMed ID: 1686127
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of donepezil on verbal memory after semantic processing in healthy older adults.
    FitzGerald DB; Crucian GP; Mielke JB; Shenal BV; Burks D; Womack KB; Ghacibeh G; Drago V; Foster PS; Valenstein E; Heilman KM
    Cogn Behav Neurol; 2008 Jun; 21(2):57-64. PubMed ID: 18541979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological replacement of cholinergic function in Alzheimer disease.
    Giacobini E
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():412A-413A. PubMed ID: 1498895
    [No Abstract]   [Full Text] [Related]  

  • 35. Alzheimer's disease and somatostatin: a therapeutic hypothesis.
    Vécsei L
    Biol Psychiatry; 1993 Nov; 34(10):673-5. PubMed ID: 7904831
    [No Abstract]   [Full Text] [Related]  

  • 36. Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
    Shankle WR; Hara J; Mangrola T; Hendrix S; Alva G; Lee MD
    Alzheimers Dement; 2013 Jul; 9(4):422-8. PubMed ID: 23123230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.
    Francis PT; Palmer AM; Sims NR; Bowen DM; Davison AN; Esiri MM; Neary D; Snowden JS; Wilcock GK
    N Engl J Med; 1985 Jul; 313(1):7-11. PubMed ID: 2582256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Remarks on the drug treatment of demented patients].
    Wettstein A
    Schweiz Arch Neurol Psychiatr (1985); 1985; 136(4):101-6. PubMed ID: 2413531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic frontiers in Alzheimer's disease.
    Miller SW; Mahoney JM; Jann MW
    Pharmacotherapy; 1992; 12(3):217-31. PubMed ID: 1608856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.